Search results for: Professor Adrian Towse
Filter search results
Towse at ISPOR: Macro HTA and Managed Entry Agreements
7 October 2014
Adrian Towse, currently President of ISPOR, contributed to two session at the recent ISPOR Asia-Pacific conference. Using HTA to maximise health system performance: Health technology assessment (HTA) is familiar as…
OHE at HTAi Oslo: A New Drug Development Paradigm, and the Effect of NICE Decisions Abroad
19 June 2015
…Adrian Towse then presented The NDDP project – Implications for Drug Development. Towse nddp implications for drug development v1 from Office of Health Economics Sean Tunis facilitated a…
Spotlight on OHE: Measuring Preferences, HTA Benchmarking, Value-Based Pricing, and Rationing
13 October 2011
…the third ISPOR Latin American Conference. With Lou Garrison, University of Washington, Adrian Towse presented the findings of a study by the Office of Health Economics and Veritech. Adrian presented…
Personalised Medicine: Economic Incentives for Evidence Generation
28 October 2013
Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the…
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
In November, ISPOR Europe was hosted in person for the first time since 2019 at the Austria Centre, Vienna. In front of a full theatre, OHE’s Professor Adrian Towse introduced…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
Towse and Drummond take a critical look at deficiencies in policy and suggest revisions. An editorial just published by OHE’s Adrian Towse and Michael Drummond of the University of York…
Spotlight on OHE: Assessing Value and Balancing Needs in Health Care
15 December 2011
…discussed the principles and practice of VPB in the UK policy context at the European Pharmaceutical Pricing and Reimbursement conference in October. Adrian Towse was a panellist in the VPB…
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
Adrian Towse presented evidence that transparency of process reduced corruption and improved competition. Evidence was, however, against price transparency for on-patent medicines. It will reduce access in low income countries….
Funding Challenges in the Malaysian Health Care System
7 January 2020
Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in Malaysia; and the potential…